Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis

por Hu, Ran, Zhao, Zhiting, Shi, Yue, Shi, Meiqi, Xia, Guohao, Yu, Shaorong, Feng, Jifeng
Publicado 2021

A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

por Wu, Ranpu, Yu, Shaorong, Ye, Jinjun, Wang, Yimin, Zhao, Zhiting, Liu, Hongbing, Song, Yong
Publicado 2021

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

por Zhao, Zhiting, Zhao, Luqing, Xia, Guohao, Lu, Jianwei, Shen, Bo, Zhou, Guoren, Wu, Fenglei, Hu, Xiao, Feng, Jifeng, Yu, Shaorong
Publicado 2023